Phase II Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas
Phase of Trial: Phase II
Latest Information Update: 09 Apr 2019
Price : $35 *
At a glance
- Drugs Imatinib (Primary)
- Indications Plexiform neurofibroma
- Focus Therapeutic Use
- 04 Apr 2019 Status changed from recruiting to discontinued.
- 12 Apr 2016 Planned End Date changed from 1 Dec 2019 to 1 Dec 2020.
- 03 Jul 2014 New trial record